Orencia Go Patient Materials

Learn more about your treatment with ORENCIA^® (abatacept)

UPDATE: RESOLUTION OF ORENCIA (ABATACEPT) SHORTAGE

BMS Australia is pleased to advise that the Orencia (abatacept) subcutaneous (SC) presentations shortage has been resolved. What this means is:

The Serious Scarcity Substitution Instrument (SSSI) and the TGA shortage notification for the SC preparations of Orencia is no longer in place.
The Orencia Stock Hypercare Plan (OSHP) has ceased and normal prescribing and ordering processes for all Orencia presentations has resumed.
Patients may switch back to, and new patients may be initiated on, any of the Orencia presentations (IV or SC) as deemed appropriate by their treating physician.

BMS wishes to thank patients, their treating physicians, and pharmacists for their patience, understanding and support during this extremely challenging situation. We recognise that the need to reduce the usage of Orencia during this time has been difficult for all to achieve and we wish to convey our sincerest appreciation.

BMS would also like to extend our thanks to the TGA, Australian Rheumatology Association and Arthritis Australia as well as Creaky Joints for their collaboration and support during this time.

BMS knows the importance of a steady and reliable supply of critical medicines for patients and remains committed to delivering Orencia to patients in Australia.